International Society for antiviral research

Home
ICAR2021
Schedule

34th International Conference on Antiviral Research (ICAR)

SCHEDULE

Schedule for live sessions is listed below.

All presentations are available on-demand for registered attendees starting March 15, 2021.

All content will be available through April 25, 2021.

REGISTER NOW

View ICAR2021 Program & Abstracts Book

Access Virtual Platform

*Note that all times are listed in US Eastern Time.

Monday, March 22, 2021
11:00 AM - 12:15 PM ET	Opening Session Q&A Session 1: Influenza/RSV Chaired by María-Jesús Pérez-Pérez and Johan Neyts Louis Bont, MD, PhD, University Medical Center Utrecht, The Netherlands Treating RSV infection Rachel Fearns, PhD, Boston University School of Medicine, Massachusetts, USA The polymerase complex of the non-segmented negative strand RNA viruses: differences in initiation mechanisms Ron Fouchier, PhD, Erasmus MC Rotterdam, The Netherlands Now that we have the world’s attention: Influenza! Additional short presentations
12:15 PM - 1:15 PM ET	Special Event: Women in Science Roundtable
7:30 PM - 8:30 PM ET	Poster Session 1A
8:30 PM - 9:00 PM ET	Speed Networking Session 1
9:00 PM - 10:00 PM ET	*Q&A Session 2: Pandemic Preparedness (dedicated to Mark Prichard)* and Gertrude Elion Memorial Award** Chaired by Pei-Yong Shi and Rich Whitley William Lee, PhD, Gilead Sciences, California, USA 2021 Gertrude Elion Memorial Award Recipient Defining Innovation in the Quest for Treatment, Prevention and Cure of Viral Diseases Tomas Cihlar, PhD, Gilead Sciences, California, USA Antivirals and preparedness for pandemics: what we have and what we need Philip Dormitzer, MD, PhD, Pfizer, Inc., New York, USA Scientific basis for the rapid development of highly effective RNA-based COVID-19 vaccines Pei-Yong Shi, PhD, University of Texas Medical Branch, USA SARS-CoV-2 biology and countermeasure development Additional short presentations

Tuesday, March 23, 2021
11:00 AM - 11:45 AM ET	Q&A Session 3: COVID-19 Vaccines Chaired by Rhonda Cardin and Kara Carter Ann Arvin, MD, Stanford University; Senior Advisor, Vir Biotechnology, California, USA A perspective on viral vaccine immunity and the issue of disease enhancement Florian Krammer, PhD, Icahn School of Medicine at Mount Sinai, New York, USA Antibody responses to the SARS-CoV-2 spike protein Hanneke Schuitemaker, PhD, Janssen Vaccines & Prevention B.V., The Netherlands Janssen’s effort in the development of an Ad26 based COVID-19 vaccine Tal Zaks, MD, PhD, Moderna, Massachusetts, USA Overview of Moderna COVID-19 vaccine: safety, immunogenicity and efficacy
11:45 AM - 12:15 PM ET	Speed Networking Session 2
12:15 PM - 1:15 PM ET	Poster Session 2A
1:15 PM - 2:15 PM ET	Special Event: Career Development Interactive Workshop Prof. Jen Heemstra, PhD, Associate Chemistry Professor at Emory University You belong: finding confidence in the face of self-doubt and impostor syndrome
8:00 PM - 9:00 PM ET	Q&A Session 4: COVID-19 Therapeutics and Diversity Speaker Award Chaired by Luis Schang and Kathie Seley-Radtke Craig Cameron, PhD, University of North Carolina School of Medicine, USA 2021 Diversity Speaker Award Recipient My career-long fascination with antiviral therapeutics Bruno Canard, PhD, University of Marseille, France The SARS-CoV1 and 2 replication/transcription machinery and its future for drug-design Kyeong-Ok Chang, DVM, MS, PhD, College of Veterinary Medicine Kansas State University Development of small molecule protease inhibitors against SARS-CoV-2 Christoph Nitsche, PhD, Australian National University Targeting the Proteases of SARS-CoV-2 and Other RNA Viruses John Pierre "JP" Sommadossi, PhD, Atea Pharmaceuticals AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19 Additional short presentations
9:00 PM - 9:45 PM ET	Q&A Session 5: Retroviruses and Herpes Viruses Chaired by Galit Alter and Tomas Cihlar Christine Johnston, MD, MPH, University of Washington HSV-1 and Alzheimer’s Disease: causation or association? Understanding the biologic plausibility Robert Siliciano, MD, PhD, Johns Hopkins University School of Medicine Barriers to curing HIV infection Jennifer Zhang, MS, Gilead Sciences Lenacapavir: A first-in-class phase 2/3 HIV capsid inhibitor with potential for twice yearly dosing Additional short presentations

Wednesday, March 24, 2021
11:00 AM - 12:00 PM ET	Poster Session 1B
12:00 PM - 12:45 PM ET	Q&A Session 6: Other Viruses and Women in Science Speaker Award Chaired by Chris Meier and Joana Rocha-Pereira Graciela Andrei, PhD, Faculty of Medicine, KU Leuven 2021 Women in Science Speaker Award Recipient Genetic diversity and evolution of herpesviruses Judith Breuer, PhD, Great Ormond Street Hospital for Children Antiviral agents for serious RNA virus infections; a personalised medicine approach Jeroen Kortekaas, PhD, Wageningen Bioveterinary Research (WBVR) Four-segmented Rift Valley fever virus as a novel live-attenuated vaccine for animal and human use Maria Rosenthal, PhD, Bernhard Nocht Institute for Tropical Medicine Understanding the multiple functions of the bunyavirus polymerase protein Additional short presentations
12:45 PM - 1:00 PM ET	ISAR Annual Business Meeting
8:00 PM - 9:00 PM ET	Poster Session 2B
9:00 PM - 9:45 PM ET	Q&A Session 7: Arboviruses Chaired by Justin Julander and Subhash Vasudevan Mark Heise, PhD, University of North Carolina School of Medicine New strategies for modeling and treating emerging viral pathogens Jenny Low, MBBS, MRCP, MPH, Duke-NUS Medical School/SingHealth Biologics as therapeutics for rapid outbreak response - can we get there fast enough? Johan Neyts, PhD, University of Leuven, Belgium Pan-serotype dengue virus inhibitor that blocks the NS3-NS4B interaction and exhibits unprecedented in vivo potency Additional short presentations

Thursday, March 25, 2021
11:00 AM - 11:45 AM ET	Q&A Session 8: Hepatitis Viruses and William Prusoff Memorial Award Chaired by Jerome Deval and David Durantel David Durantel, PhD, Center for Infectiology Research of Lyon (CIRI)- INSERM U1111 2021 William Prusoff Memorial Award Recipient Mid-term report on my academic journey to discover novel HBV/HDV therapeutics Adam Gehring, PhD, Toronto Centre for Liver Disease Towards combination treatments for Chronic Hepatitis B: an immunologist’s point of view Eike Steinmann, PhD, Ruhr University Bochum Principles of Hepatitis E virus replication, persistence and antiviral strategies John Tavis, PhD, Saint Louis University School of Medicine Towards combination treatments for chronic hepatitis B: A virologist point of view Additional short presentations
11:45 AM - 12:30 PM ET	Q&A Session 9: Technology and Antonín Holý Memorial Award Chaired by Andrea Brancale and Jennifer Moffatt Eddy Arnold, PhD, Center for Advanced Biotechnology and Medicine, Rutgers University 2021 Antonín Holy Memorial Award Recipient The long and winding road: 35 Years of HIV reverse Transcriptase structure, mechanism, and successful anti-AIDS drug design Matthew Disney, PhD, The Scripps Research Institute Sequence-based design of small molecules targeting RNA Chris Meier, PhD, Universität Hamburg, Germany Design of nucleotide prodrugs for antiviral chemotherapy – the TriPPPro-Approach Christiane Wobus, PhD, University of Michigan Medical School Investigating enterotropic virus infections in human intestinal organoids
12:30 PM - 1:30 PM ET	Special Event: PechaKucha Competition
7:00 PM - 8:45 PM ET	Q&A Session 10: Other Respiratory Viruses Chaired by Mike Lo and Robert Jordan Hector Aguilar-Carreno, PhD, Cornell University Emerging deadly viruses and their glycoproteins - From infection to vaccines and antivirals Emmie de Wit, PhD, NIAID Remdesivir treatment for emerging virus infections James Gern MD, University of Wisconsin School of Medicine and Public Health The ABCs of rhinovirus infections and asthma Additional short presentations Closing Session

Agenda Snapshot

About ISAR

The International Society for Antiviral Research (ISAR) is an internationally recognized organization for scientists involved in basic, applied, and clinical aspects of antiviral research. The Society main event is the annual International Conference on Antiviral Research (ICAR), a truly interdisciplinary meeting which attracts the interest of chemists, biologists, and clinicians.

ISAR

info@isaricar.com
1-571-349-0079